Influence of organic anion transporter 1/3 on the pharmacokinetics and renal excretion of ginkgolides and bilobalide.


Journal

Journal of ethnopharmacology
ISSN: 1872-7573
Titre abrégé: J Ethnopharmacol
Pays: Ireland
ID NLM: 7903310

Informations de publication

Date de publication:
28 Oct 2019
Historique:
received: 23 04 2019
revised: 09 07 2019
accepted: 16 07 2019
pubmed: 22 7 2019
medline: 6 2 2020
entrez: 21 7 2019
Statut: ppublish

Résumé

The major terpene lactones of ginkgo biloba extract (GBE) include ginkgolide A, B, C and bilobalide are used for the protection of cardiovascular, cerebrovascular and neurodegenerative diseases. Terpene lactones are orally bioavailable and predominantly eliminated via the renal pathway. However, information on the transporters involved in the pharmacokinetics (PK) and renal excretion of terpene lactones is limited. The objective of this study is to assess the role of OAT1/3 which are important transporters in the human kidney in the PK and renal excretion ginkgolide A, B, C and bilobalide. Uptake of ginkgolide A, B, C and bilobalide in Madin-Darby Canine Kidney (MDCK) and human embryonic kidney 293 (HEK293) cells overexpressing OAT1 or OAT3, respectively were studied. To verify the result from in vitro cell models, the studies on PK, kidney accumulation and urinary excretion of ginkgolide A, B, C and bilobalide were carried out in rats. The result showed that ginkgolide A, B, C and bilobalide are low-affinity substrates of OAT1/3. Following co-administration with probenecid, a typical inhibitor of OAT1/3, the rat plasma concentrations of ginkgolide A, B, C and bilobalide increased significantly. AUC showed a significant increase in the probenecid-treated rats compared to control rats (893.48 vs. 1123.85, 314.91 vs. 505.74, and 2724.97 vs. 3096.40 μg/L*h for ginkgolide A, B and bilobalide, respectively), while the clearance of these compounds significantly decreased. The accumulation of ginkgolide A, B and bilobalide in the kidney of the probenecid-treated rats was reduced by 1.8, 2.4, and 1.5-fold, respectively; further reducing the cumulative urinary recovery of these compounds. The findings indicated that ginkgolide A, B and bilobalide are excreted via OAT1/3-mediated transport in the kidney and OAT1/3 inhibitor significantly influence the PK ginkgolides and bilobalide.

Identifiants

pubmed: 31325605
pii: S0378-8741(19)31576-4
doi: 10.1016/j.jep.2019.112098
pii:
doi:

Substances chimiques

Cyclopentanes 0
Furans 0
Ginkgolides 0
Organic Anion Transport Protein 1 0
Organic Anion Transporters, Sodium-Independent 0
organic anion transport protein 3 0
bilobalide M81D2O8H7U

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112098

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Peter Yaro (P)

Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.

Jing Nie (J)

Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.

Mingcheng Xu (M)

Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.

Kui Zeng (K)

Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.

Houhong He (H)

Zhejiang Conba Pharmaceutical Co., Ltd, Zhejiang Provincial Key Laboratory of TCM Pharmaceutical Technology, Hangzhou, 310006, China.

Jianbiao Yao (J)

Zhejiang Conba Pharmaceutical Co., Ltd, Zhejiang Provincial Key Laboratory of TCM Pharmaceutical Technology, Hangzhou, 310006, China.

Ruwei Wang (R)

Zhejiang Conba Pharmaceutical Co., Ltd, Zhejiang Provincial Key Laboratory of TCM Pharmaceutical Technology, Hangzhou, 310006, China.

Su Zeng (S)

Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. Electronic address: zengsu@zju.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH